Aliskiren in the treatment of hypertension and organ damage

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Hypertension is a major risk factor for cardiovascular diseases (CVD), cardiac, and renal conditions.
• Chronic activation of the renin-angiotensin-aldosterone system (RAAS) is implicated in hypertension and organ damage.
• Current RAAS inhibitors (ACEI, ARBs) improve outcomes but leave significant residual risk.

Purpose of the Study:

• To review the efficacy, safety, and tolerability of aliskiren, a direct renin inhibitor.
• To evaluate the potential organ-protective benefits of aliskiren therapy.
• To explore comprehensive RAAS blockade for improved clinical outcomes.

Main Methods:

• Review of clinical trial data on aliskiren.
• Analysis of aliskiren's mechanism of action compared to ACEI and ARBs.
• Examination of evidence for aliskiren's effects on cardiovascular and renal endpoints.

Main Results:

• Aliskiren targets RAAS at its activation point, reducing plasma renin activity.
• Unlike ACEI and ARBs, aliskiren does not increase plasma renin activity.
• Ongoing trials are assessing aliskiren's impact on major clinical events.

Conclusions:

• Direct renin inhibition with aliskiren represents a novel strategy for RAAS blockade.
• Aliskiren has the potential to offer additional benefits in reducing morbidity and mortality in hypertensive patients.
• Further evidence from clinical trials is needed to confirm aliskiren's organ protection and clinical event reduction capabilities.